Hana Biosciences, Inc. Initiates Phase I Clinical Trial Of A Targeted Chemotherapy Agent For Patients With Advanced Solid Tumors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 3, 2006--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the initiation of a Phase I clinical study of Sphingosome Encapsulated Vinorelbine in patients with advanced solid tumors.